Skip to content
Home › Funds › a16z
Venture capital · Q3 2026 13F recap

a16z (Andreessen Horowitz): Q3 2026 13F

Silicon Valley venture firm; its 13F shows the public stakes it holds after IPOs.

Holdings as of Sep 30, 2026 (Q3 2026)Filed Nov 16, 202613F deadline Nov 16, 2026 (45 days after quarter end)

$19.9B
stocks & ETFs (13F)
24
positions
6
new positions
1
sold out
—
options (notional)
PostLinkedIn

Portfolio at a glance

Largest stock and ETF positions sized by weight, coloured by change since the previous 13F.

SPCX · Space Exploration Techn Corp: 92.3% · Added toSPCX92.3%NAVN · Navan Inc: 3.0% · UnchangedNAVNBRVE · Braveheart Bio Inc: 1.0% · NewBRVERVMD · Revolution Medicines Inc: 0.8% · TrimmedRVMDFRNM · Freenome Inc: 0.4% · NewLIME · Neutron Holdings Inc: 0.4% · NewXYZ · Block Inc: 0.4% · UnchangedSCTX · Scribe Therapeutics Inc: 0.3% · NewFIG · Figma Inc: 0.3% · TrimmedMAZE · Maze Therapeutics Inc: 0.2% · UnchangedSTDN · Standard Nuclear Inc: 0.2% · NewDMRA · Damora Therapeutics Inc: 0.1% · UnchangedBIOA · Bioage Labs Inc: 0.1% · UnchangedERAS · Erasca Inc: 0.1% · TrimmedMETA · Meta Platforms Inc: 0.1% · TrimmedRBLX · Roblox Corp: 0.1% · UnchangedCAMP · Camp4 Therapeutics Corp: 0.0% · UnchangedAKTS · Aktis Oncology Inc: 0.0% · UnchangedBTGO · Bitgo Holdings Inc: 0.0% · UnchangedNAUT · Nautilus Biotechnology Inc: 0.0% · TrimmedBLSM · Blossomhill Therapeutics Inc: 0.0% · NewKLRA · Kailera Therapeutics Inc: 0.0% · UnchangedDNA · Ginkgo Bioworks Holdings Inc: 0.0% · Unchanged
Box size = share of the reported portfolio.Added toUnchangedNewTrimmed

Biggest moves

Estimated dollars bought and sold in Q3 2026 (change in shares × quarter-end price).

◀ SoldBought ▶
  • SPCX+$7.1B
  • BRVENEW+$207M
  • FRNMNEW+$88M
  • LIMENEW+$80M
  • SCTXNEW+$57M
  • STDNNEW+$35M
  • BLSMNEW+$2M
  • META−$139M
  • FIG−$72M
  • RVMD−$28M
  • OMDAOUT−$25M
  • ERAS−$21M
  • NAUT−$9M

Top buys

Ranked by estimated dollars added: change in shares × quarter-end price.

a16z top buys
StockChangeEst. $
Space Exploration Techn Corp
Added+62.7%+$7.1B
BRVE
Braveheart Bio Inc
New+$207M
FRNM
Freenome Inc
New+$88M
LIME
Neutron Holdings Inc
New+$80M
SCTX
Scribe Therapeutics Inc
New+$57M
STDN
Standard Nuclear Inc
New+$35M
BLSM
Blossomhill Therapeutics Inc
New+$2M

Top sales

Ranked by estimated dollars sold, including full exits.

a16z top sales
StockChangeEst. $
Meta Platforms Inc
Trimmed-90.1%−$139M
Figma Inc
Trimmed-57.1%−$72M
Revolution Medicines Inc
Trimmed-15%−$28M
OMDA
Omada Health Inc
Sold out−$25M
ERAS
Erasca Inc
Trimmed-50%−$21M
NAUT
Nautilus Biotechnology Inc
Trimmed-70.7%−$9M

New positions

StockChangeEst. $
BRVE
Braveheart Bio Inc
New+$207M
FRNM
Freenome Inc
New+$88M
LIME
Neutron Holdings Inc
New+$80M
SCTX
Scribe Therapeutics Inc
New+$57M
STDN
Standard Nuclear Inc
New+$35M
BLSM
Blossomhill Therapeutics Inc
New+$2M

Sold out

StockChangeEst. $
OMDA
Omada Health Inc
Sold out−$25M

Largest holdings

Top 24 of 24 stock and ETF positions, as of Sep 30, 2026. Options are listed separately below.

StockChangeValue
Space Exploration Techn Corp
Added+62.7%$18.4B
NAVN
Navan Inc
Unchanged$592M
BRVE
Braveheart Bio Inc
New$207M
Revolution Medicines Inc
Trimmed-15%$161M
FRNM
Freenome Inc
New$88M
LIME
Neutron Holdings Inc
New$80M
Block Inc
Unchanged$75M
SCTX
Scribe Therapeutics Inc
New$57M
Figma Inc
Trimmed-57.1%$54M
MAZE
Maze Therapeutics Inc
Unchanged$46M
STDN
Standard Nuclear Inc
New$35M
DMRA
Damora Therapeutics Inc
Unchanged$26M
BIOA
Bioage Labs Inc
Unchanged$23M
ERAS
Erasca Inc
Trimmed-50%$21M
Meta Platforms Inc
Trimmed-90.1%$15M
Roblox Corp
Unchanged$12M
CAMP
Camp4 Therapeutics Corp
Unchanged$9M
AKTS
Aktis Oncology Inc
Unchanged$8M
BTGO
Bitgo Holdings Inc
Unchanged$5M
NAUT
Nautilus Biotechnology Inc
Trimmed-70.7%$4M
BLSM
Blossomhill Therapeutics Inc
New$2M
KLRA
Kailera Therapeutics Inc
Unchanged$2M
DNA
Ginkgo Bioworks Holdings Inc
Unchanged$1M
IPST
Ip Strategy Holdings Inc
Unchanged$13K

Source: a16z Capital Management, L.L.C., Form 13F-HR on SEC EDGAR, compared with the filing for Jun 30, 2026. 13F shows only US-listed long positions (plus listed options), is delayed up to 45 days, and estimated dollar changes assume the quarter-end price. Not investment advice. How we calculate this.

All 110 funds → · Q3 2026 recap of every fund →

Weekly digest · free

13F filings and guru moves, in one short email

A Sunday digest of what famous investors said and filed this week, plus an alert when someone changes stance. Free, no spam, unsubscribe anytime.